About PEB
Pacific Edge Limited (PEB) operates as a global cancer diagnostics organisation focused on development and commercialisation of bladder cancer diagnostic and prognostic tests for individuals presenting with hematuria or under surveillance for recurrent disease. Based in Dunedin, New Zealand, the organisation delivers the Cxbladder test suite through wholly owned CLIA certified laboratories located in New Zealand and the United States.
Find out what a historical investment in Pacific Edge would be worth today using our PEB stock calculator.
Market Capitalisation
$235.96M
Price-earnings ratio
-5.99
Dividend yield
-
High today
$0.19
Low today
$0.19
Open price
$0.19
52-week high
$0.27
52-week low
$0.12
Ready to start your investing journey with Stake?
Open an accountAnnouncements
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in PEB
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.

Invest in PEB on Stake
- Buy PEB from A$3 brokerage
- Invest in 2,500+ Aussie stocks and ETFs
- CHESS-sponsored ASX trades
Stock shown for demonstrative purposes only. A$3 brokerage up to A$30,000.
PEB related stocks